Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Slides:

Advertisements

Similar presentations

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

Advertisements

Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H.

A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Cryopreservation of supernumerary high quality embryos predicts favorable outcomes for patients undergoing repeated cycles of in vitro fertilization

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D. Fertility and Sterility

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

An initial low response predicts poor outcome in in vitro fertilization/intracytoplasmic sperm injection despite improved ovarian response in consecutive.

Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization.

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone–stratified, dose–response trial in women undergoing.

Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and.

Changes in affect and state anxiety across an in vitro fertilization/intracytoplasmic sperm injection cycle Neha N. Mahajan, Ph.D., Deborah A. Turnbull,

Initial experience with a risk-sharing in vitro fertilization–embryo transfer program with novel features Jacques P. Stassart, M.D., Romaine B. Bayless,

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Multinucleation in normally fertilized embryos is associated with an accelerated ovulation induction response and lower implantation and pregnancy rates.

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Economic evaluation of elective single-embryo transfer with subsequent single frozen embryo transfer in an in vitro fertilization/intracytoplasmic sperm.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial Robert Boostanfar, M.D.,

Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins

Initial IVF-ET experience with assisted hatching performed 3 days after retrieval followed by day 5 embryo transfer Margaret C. Graham, M.S., Kathleen.

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles Eva R. Groenewoud, M.D.,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Cumulative probability of live birth after three in vitro fertilization/intracytoplasmic sperm injection cycles Katarina Olivius, B.Sc., Barbro Friden,

Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles? Mae Wu Healy, D.O., George Patounakis, M.D.,

Nondominant small follicles are a promising source of mature oocytes in modified natural cycle in vitro fertilization and embryo transfer Shokichi Teramoto,

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Number of good quality embryos on day 3 is predictive for both pregnancy and implantation rates in in vitro fertilization/intracytoplasmic sperm injection.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Poor sperm quality affects clinical outcomes of intracytoplasmic sperm injection in fresh and subsequent frozen–thawed cycles: potential paternal effects.

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Hongxia Li, M. D. , Steven T Nakajima, M. D. , Jiangang Chen, M. D

Clazien A. M. Bouwmans, M. Sc. , Bea M. E. Lintsen, M. D. , Marinus J

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization–embryo transfer cycle outcome Eric S Surrey,

Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer Jennifer L Phy, D.O., William T Weiss, R.Ph., Catherine R Weiler,

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal.

Barry Behr, Ph.D., H.C.L.D., Amin A Milki, M.D.

In Vitro Fertilization (IVF) Intracytoplasmic Sperm Injection (ICSI) Using Sperm Exposed to Cyclophosphamide Reduces Preimplantation Embryo Development.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Sperm deoxyribonucleic acid fragmentation as a prognostic indicator of assisted reproductive technology outcome Mehdi Benchaib, M.D., Ph.D., Jacqueline.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil.,

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

In vitro sildenafil citrate use as a sperm motility stimulant

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

William R. Boone, Ph. D. , Jeffrey M. Jones, Ph. D. , Sander S

Peter M. Martin, M.D., H.Gilbert Welch, M.D. Fertility and Sterility

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society.

Presentation transcript:

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States Kaylen Silverberg, M.D., Salim Daya, M.B., M.Sc., Jean Paul Auray, Ph.D., Gerald Duru, Ph.D., William Ledger, Matts Wikland, M.D., Ph.D., Renda Bouzayen, M.D., Mark O’Brien, M.D., Barri Falk, M.S., Ariel Beresniak, M.D., Ph.D. Fertility and Sterility Volume 77, Issue 1, Pages 107-113 (January 2002) DOI: 10.1016/S0015-0282(01)02945-4

FIGURE 1 Simplified representation of the Markov model, illustrating all possible complete treatment and frozen ET cycles that can occur during a three-cycle treatment program using recombinant human FSH. An identical representation is used for treatment with urinary FSH. Silverberg. Cost effectiveness of recombinant human FSH vs. urinary FSH. Fertil Steril 2002. Fertility and Sterility 2002 77, 107-113DOI: (10.1016/S0015-0282(01)02945-4)

FIGURE 2 Markov model illustrating all possible stages of a single cycle of a three-cycle treatment program using recombinant human FSH with fresh embryos. Silverberg. Cost effectiveness of recombinant human FSH vs. urinary FSH. Fertil Steril 2002. Fertility and Sterility 2002 77, 107-113DOI: (10.1016/S0015-0282(01)02945-4)

FIGURE 3 Markov model illustrating all possible stages of a single cycle of a three-cycle treatment program using recombinant human FSH with frozen/thawed embryos. Silverberg. Cost effectiveness of recombinant human FSH vs. urinary FSH. Fertil Steril 2002. Fertility and Sterility 2002 77, 107-113DOI: (10.1016/S0015-0282(01)02945-4)